Advertisement


Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy

2023 ASCO Annual Meeting

Advertisement

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses waveLINE-007, a two-part study now recruiting in more than 20 locations, to determine the safety and recommended phase II dose of the antibody-drug conjugate zilovertamab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). Efficacy of this regimen will be investigated in the second half of the study (Abstract TPS7589).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Muhit Özcan: Diffuse large B-cell lymphoma is typically treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, a regimen known as R-CHOP, but novel therapies are needed. A recent phase III study showed that replacing vincristine in R-CHOP with the antibody-drug conjugate polatuzumab vedotin was a viable approach in diffuse large B-cell lymphoma. ROR1 is an onco-fetal transmembrane protein that's expressed in a number of hematological malignancies, including diffuse large B-cell lymphomas. Zilovertamab vedotin is an antibody-drug conjugate comprising an anti-ROR1 antibody plus a cleavable linker, and the antimicrotubule cytotoxin monomethyl auristatin E, that has shown promising efficacy and manageable safety in patients with relapse or refractory hematological malignancies. The single-arm, open-label, phase II waveLINE-007 study has been designed to investigate zilovertamab vedotin in combination with R-CHP in patients with previously untreated diffuse like B cell lymphomas. Part one is being conducted to determine the safety and tolerability and recommended phase II dose of zilovertamab vedotin plus R-CHOP. Part two will be conducted to investigate the efficacy of zilovertamab vedotin plus R-CHP at the recommended phase II dose. The primary objectives of waveLINE-007 are to evaluate complete response rate based on Lugano criteria and to evaluate the safety and tolerability of zilovertamab vedotin plus R-CHP. Secondary objectives include evaluating objective response rate and the duration of response per Lugano criteria. Progression-free survival, overall survival, and the pharmacokinetics of zilovertamab vedotin plus R-CHP are exploratory. In part one, which is the dose escalation and confirmation part of the study, approximately 45 patients will receive treatment with zilovertamab vedotin plus R-CHP. The starting dose of zilovertamab vedotin is 1.75 milligram per kilogram plus R-CHP administered intravenously every 3 weeks for six cycles. Dose escalation will be based on the modified toxicity probability interval design up to a minimum of 2.5 milligram per kilogram, with the target dose limiting toxicity rate of 30%. In part one, which is the dose escalation and confirmation part of the study, approximately 45 patients with receive treatment with zilovertamab vedotin plus R-CHP. The starting dose of zilovertamab vedotin is 1.75 milligram per kilogram plus R-CHP administered intravenously every 3 weeks for six cycles. Dose escalation will be based on the modified toxicity probability interval design up to a maximum of 2.5 milligram per kilogram, with a target dose limiting toxicity rate of 30%. In the event of dose-limiting toxicities at the starting dose, the dose can also be deescalated to 1.5 milligram per kilogram. In part two, approximately 30 patients with received zilovertamab vedotin at the recommended phase II dose plus R-CHP intravenously every 3 weeks for six cycles or up to eight cycles for patients with high-risk disease. Eligible patients must be 18 years or older, have histologically confirmed diffuse large B cell lymphoma per WHO criteria, have PET-positive disease, have an ECOG performance status 0 or 1, and have an adequate organ function. Patients must not have received prior treatments for diffuse large B cell lymphoma patients with a history of transformation of indolent disease at diagnosis of primary mediastinal B-cell lymphoma, ongoing peripheral neuropathy of grade 2 or higher, or active central nervous system lymphoma will be excluded. Recruitment for waveLINE-007 is currently ongoing in Canada, Israel, Italy, Poland, Korea, Spain, and Turkey. Results from the waveLINE-007 study will provide insight into the efficacy and safety of zilovertamab vedotin plus R-CHP in patients with previously untreated diffuse large B-cell lymphomas.

Related Videos

Skin Cancer
Immunotherapy

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab

Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses phase I/II results on the efficacy of nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma. The study found that, for this rare and aggressive skin cancer, nivolumab showed clinical activity in advanced disease. However, these results from CheckMate 358 do not suggest an additional benefit with ipilimumab added to nivolumab (Abstract 9506).

 

Skin Cancer
Immunotherapy

Omid Hamid, MD, on Advanced Melanoma: Durable Response With Fianlimab Plus Cemiplimab

Omid Hamid, MD, of The Angeles Clinic & Research Institute, discusses study findings on fianlimab plus cemiplimab-rwlc, which showed clinical activity in patients with advanced melanoma, comparing favorably with other approved combinations of immune checkpoint inhibitors in the same clinical setting. This is the first indication that dual LAG-3 blockade may produce a high level of activity with significant overall response rate after adjuvant anti–PD-1 treatment. A phase III trial of this regimen in treatment-naive patients with advanced melanoma is ongoing (Abstract 9501).

Lymphoma

Reid Merryman, MD, on High-Risk Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Reid Merryman, MD, of Dana-Farber Cancer Institute, discusses his findings on the regimen of epcoritamab plus rituximab and lenalidomide for patients with high-risk follicular lymphoma. Regardless of whether their disease progressed within 24 months of first-line chemoimmunotherapy, this regimen showed antitumor activity and a manageable safety profile in patients with relapsed or refractory disease. Epcoritamab, a subcutaneous T-cell–engaging bispecific antibody, may abrogate the negative effects of high-risk features (Abstract 7506).

Issues in Oncology

Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary

Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses three key abstracts presented at ASCO: strategies to increase accrual of underrepresented populations in Alliance NCTN trials, how patient-clinician education can strengthen partnerships and improve diversity in breast and lung cancer trials, and mediators of racial and ethnic inequities in clinical trial participation among U.S. patients with cancer from 2011 to 2022 (Abstracts 6509, 6510, 6511).

Lymphoma

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on DLBCL: New Data on ctDNA Status and Clinical Outcomes

Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss findings from the POLARIX study, which provided the largest prospectively collected circulating tumor DNA (ctDNA) data set on patients with previously untreated diffuse large B-cell lymphoma. Achieving ctDNA-negative status was associated with improved outcomes when patients were treated with polatuzumab vedotin-piiq plus combination chemotherapy vs combination chemotherapy alone (Abstract 7523).

Advertisement

Advertisement




Advertisement